Canada, Mexico Want America to Feel the Pain of Tariffs Too
Canada and Mexico prepared to retaliate over tariffs from President Trump, as the U.S. and its neighbors spiraled into a ...
studyfinds2 小时
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
FDA approves Journavx, the first new painkiller in over two decades
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Missoulian2 天
FDA approves new painkiller that shows promise and challenges of opioid alternatives
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
Science News2 天
A new kind of non-opioid painkiller gets FDA approval
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
healthday2 天
FDA Approves First New Non-Opioid Pain Pill in Decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...
The Lancet15 天
Telerehabilitation for chronic knee pain: the PEAK trial
We praise Rana S Hinman and colleagues 1 for their comprehensive investigation into the efficacy of telerehabilitation consultations versus in-person consultations for chronic knee pain management.